Ischemix
63 Great Road
Maynard
Massachusetts
01754
United States
Tel: 978-897-5139
Fax: 978-897-4952
Website: http://www.ischemix.com/
Email: mail@ischemix.com
9 articles about Ischemix
-
Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial
8/25/2023
Ischemix, Inc., a privately-held company focused on developing cytoprotective therapeutics for serious medical conditions, today announced that it has completed an 80-subject Phase 1 clinical trial to evaluate safety, tolerability and pharmacokinetics of its drug candidate, CMX-2043, in healthy human subjects.
-
Ischemix, Inc. Receives US Department of Defense Funding of $2.9 million to Conduct Phase 1 Study of Drug Candidate to Treat Traumatic Brain Injury (TBI)
7/7/2021
Ischemix, Inc., a private company focused on developing therapeutics for serious medical conditions, announced that the US Department of Defense has made a $2.9 award to the Company to fund a Phase 1 study of CMX-2043, a novel compound for the treatment of acute TBI.
-
Ischemix Elects Peter G. Milner, MD To Board Of Directors
8/12/2015
-
Ischemix Announces That Safety Review Committee For CARIN Trial Recommends Phase 2a Study To Continue As Planned
5/20/2015
-
Ischemix Enrolls First Patient In Phase 2a Trial To Prevent Contrast-Induced Acute Kidney Injury
6/26/2014
-
Clinical-Stage Biotech Ischemix Taps DeWahl as CEO
1/10/2013
-
Ischemix Announces Positive Top Line Data from Phase 2 Clinical Trial of CMX-2043
6/17/2011
-
Ischemix Initiates Phase 2a Trial of CMX-2043 for the Prevention of Ischemia-Reperfusion Injury
3/9/2010
-
Ischemix Appoints Robert DuFresne as Chief Executive Officer
3/24/2009